[
  {
    "ts": null,
    "headline": "Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On",
    "summary": "There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading strategies.",
    "url": "https://finnhub.io/api/news?id=2d8a77002f202ebab21747b57fb0b038efb00d6852cd6f1da32ec7b2df6eff3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767983402,
      "headline": "Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On",
      "id": 138052525,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading strategies.",
      "url": "https://finnhub.io/api/news?id=2d8a77002f202ebab21747b57fb0b038efb00d6852cd6f1da32ec7b2df6eff3b"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
    "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
    "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767975542,
      "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
      "id": 138052209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
      "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767973860,
      "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
      "id": 138052210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
    "summary": "It could be another tough year for the once-soaring drugmaker.",
    "url": "https://finnhub.io/api/news?id=671086fc2166b8182cea8c946e5ccae67960b29adc6b689890d9c99fb800b77f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767970200,
      "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
      "id": 138046728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It could be another tough year for the once-soaring drugmaker.",
      "url": "https://finnhub.io/api/news?id=671086fc2166b8182cea8c946e5ccae67960b29adc6b689890d9c99fb800b77f"
    }
  },
  {
    "ts": null,
    "headline": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
    "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
    "url": "https://finnhub.io/api/news?id=e0a75d6d7d92c1cc14e1481898b4cb2eaee811fcb3ac631a14336148bb1287ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767968160,
      "headline": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
      "id": 138046679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
      "url": "https://finnhub.io/api/news?id=e0a75d6d7d92c1cc14e1481898b4cb2eaee811fcb3ac631a14336148bb1287ae"
    }
  },
  {
    "ts": null,
    "headline": "Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor",
    "summary": "Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical compa",
    "url": "https://finnhub.io/api/news?id=4fff923c6c18d1518b83c09aa2d7c6eb7af938a2dd3977091d2855de562e1f23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767963600,
      "headline": "Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor",
      "id": 138045543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical compa",
      "url": "https://finnhub.io/api/news?id=4fff923c6c18d1518b83c09aa2d7c6eb7af938a2dd3977091d2855de562e1f23"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
    "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
    "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767963421,
      "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
      "id": 138057238,
      "image": "https://image.cnbcfm.com/api/v1/image/108222520-17624504352025-11-06t173326z_182594845_rc24rhaozaeo_rtrmadp_0_usa-trump.jpeg?v=1767995336&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
      "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307"
    }
  },
  {
    "ts": null,
    "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
    "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
    "url": "https://finnhub.io/api/news?id=d54018c88b87e3d0d35e24ac04c699e68ebb10724d1fa2df4c3d059d2427aae1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767961410,
      "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
      "id": 138045475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
      "url": "https://finnhub.io/api/news?id=d54018c88b87e3d0d35e24ac04c699e68ebb10724d1fa2df4c3d059d2427aae1"
    }
  },
  {
    "ts": null,
    "headline": "Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn",
    "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...",
    "url": "https://finnhub.io/api/news?id=2fdfa40169b39d2f5d234447f960289a1c6ca3bf48d7d286265b50e05ae07af7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767919891,
      "headline": "Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn",
      "id": 138043171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...",
      "url": "https://finnhub.io/api/news?id=2fdfa40169b39d2f5d234447f960289a1c6ca3bf48d7d286265b50e05ae07af7"
    }
  },
  {
    "ts": null,
    "headline": "How Pfizer’s AI and Precision Oncology Deals At Pfizer (PFE) Have Changed Its Investment Story",
    "summary": "In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with Cartography Biosciences will use its ATLAS and SUMMIT platforms to discover tumor-selective antigens that Pfizer can advance into oncology programs. Together, these alliances highlight Pfizer’s push to use advanced AI and precision oncology tools to improve its internal pipeline productivity at a time...",
    "url": "https://finnhub.io/api/news?id=3751667749b82e168abf3d58178c152d05bdc1cf731ac1c362b0faed29a4db81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767917795,
      "headline": "How Pfizer’s AI and Precision Oncology Deals At Pfizer (PFE) Have Changed Its Investment Story",
      "id": 138043257,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with Cartography Biosciences will use its ATLAS and SUMMIT platforms to discover tumor-selective antigens that Pfizer can advance into oncology programs. Together, these alliances highlight Pfizer’s push to use advanced AI and precision oncology tools to improve its internal pipeline productivity at a time...",
      "url": "https://finnhub.io/api/news?id=3751667749b82e168abf3d58178c152d05bdc1cf731ac1c362b0faed29a4db81"
    }
  }
]